Dexcom (DXCM)
Health Care · Continuous Glucose Monitoring (CGM) Medical Devices
Dexcom designs and commercializes continuous glucose monitoring systems for diabetes and metabolic health management globally.
What Dexcom does
Dexcom is a medical device company focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for diabetes and metabolic health management. The company's flagship products include the Dexcom G7 and G7 15 Day CGM systems for insulin-using and non-insulin diabetic patients, along with Stelo, an over-the-counter glucose biosensor for adults with prediabetes and Type 2 diabetes. Dexcom's CGM systems are integrated with a connected ecosystem including insulin pumps, smart pens, wearables, and digital health apps, and are covered by Medicare, Medicaid, and commercial insurers in the United States.
Themes: ["Diabetes management and glucose monitoring","Continuous glucose monitoring (CGM)","Digital health and connected medical devices","Type 1 and Type 2 diabetes care","Metabolic health and prediabetes management","Wearable biosensors","Over-the-counter (OTC) glucose monitoring"]
Fundamentals
- Price$73.02 as of 2026-07-09 close
- Market cap$28.1B as of 2026-07-10
- 1-year return-14.0% as of 2026-07-09 close
- P/E30.18 as of 2026-07-10
- Net margin+19.3% as of 2026-07-10
- Gross margin+63.4% as of 2026-07-10
- ROE+33.8% as of 2026-07-10
- Debt / equity0.44 as of 2026-07-10
- Revenue growth (YoY)+16.1% as of 2026-07-10
- Revenue CAGR (3y)+17.0% SEC XBRL
- Beta1.43 as of 2026-07-10
Key risks (from latest filing)
["Regulatory approval and FDA clearance required for product launches; changes in regulatory requirements or special controls for CGM devices could impact product development and commercialization timelines","Reimbursement dependency on Medicare, Medicaid, and commercial insurers; changes in coverage policies or payment rates could materially impact revenue and patient access","Competition in the CGM market from other continuous glucose monitoring manufacturers; pricing pressure and market share erosion from competing products and emerging technologies"]
Competitors & peers
- Abbott Laboratories (ABT) — FreeStyle Libre CGM systems
- Medtronic (MDT) — Guardian continuous glucose monitoring systems
- Senseonics Holdings (SENS) — Eversense implantable CGM
- GlucoTrack and other emerging OTC glucose monitoring entrants
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.